Cargando…

Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review

Background: Immune checkpoint inhibitor (ICI) therapy is now administered to patients with advanced cancers. However, the safety and efficacy of ICIs in cancer patients with hepatitis B virus (HBV) infection is unknown. Therefore, we performed this systematic review to examine the safety and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jian, Zhang, Yuehua, Qin, Siyuan, Zou, Bingwen, Wang, Yongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723987/ https://www.ncbi.nlm.nih.gov/pubmed/36484006 http://dx.doi.org/10.7150/jca.77247

Ejemplares similares

Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Burns, Ethan A., et al.
Publicado: (2021)

Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Xia, Zhengzheng, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
por: Alkrekshi, Akram, et al.
Publicado: (2021)

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors
por: Wang, Mu-Qi, et al.
Publicado: (2022)

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
por: Zhang, Xuanye, et al.
Publicado: (2019)

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis
por: Dong, Huijing, et al.
Publicado: (2023)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis
por: Niu, Zhicheng, et al.
Publicado: (2021)

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
por: Patrinely, J. Randall, et al.
Publicado: (2021)

Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment
por: Kuo, Meng Hsuan, et al.
Publicado: (2021)

Immune checkpoint inhibitors in the treatment of virus-associated cancers
por: Gao, Peipei, et al.
Publicado: (2019)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors
por: Shen, Jiaming, et al.
Publicado: (2023)

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
por: Shah, Neil J., et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
por: Tagliamento, Marco, et al.
Publicado: (2022)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management
por: Shivaji, Uday N., et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review
por: Taherian, Mehran, et al.
Publicado: (2022)

A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?
por: Moradi, Ali, et al.
Publicado: (2023)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
por: Ando, Yosuke, et al.
Publicado: (2019)

Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy
por: Tamura, Yudai, et al.
Publicado: (2022)

Hepatitis B virus reactivation in rheumatoid arthritis
por: Wu, Ya-Li, et al.
Publicado: (2022)

Chemotherapy-induced fatal hepatitis B virus reactivation in a small-cell lung cancer patient
por: Qin, Lei, et al.
Publicado: (2016)

Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression
por: Lazarevic, Ivana, et al.
Publicado: (2019)

The Immune Response of Vaccination Against Hepatitis B virus in Iranian Patients Undergoing Chemotherapy
por: Meidani, Mohsen, et al.
Publicado: (2017)

Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL
por: Xie, Zhi-Bo, et al.
Publicado: (2016)

Toxicities associated with immune checkpoint inhibitors: a systematic study
por: Kong, Xiangyi, et al.
Publicado: (2023)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Neurotoxicity
por: Zhao, Zhiyi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vjs0p44s6cst770jaeeqbkud3l